» Articles » PMID: 26751507

Comparison of the Anti-Inflammatory Effects of Artificial Tears in a Rat Model of Corneal Scraping

Overview
Date 2016 Jan 12
PMID 26751507
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Artificial tears (ATs) are used routinely to alleviate the symptoms of mild to moderate dry eye. Preservative-free cationic emulsions (eg, Cationorm(®)) are an innovative approach for the management of signs and symptoms of dry eye. The aim of the present exploratory experiment was to evaluate the efficacy of this cetalkonium chloride (CKC)-containing cationic emulsion on debrided cornea and to characterize its effects on scraping-induced inflammation.

Methods: Four ATs were assessed in a rat model of corneal scraping. The upper part of the corneal epithelium was scraped before a 5-day treatment, followed by clinical evaluations and fluorescein staining to evaluate cornea recovery. The anti-inflammatory efficacy of the ATs was assessed in vivo and in vitro.

Results: In vivo confocal microscopy (IVCM) revealed a trend toward better corneal clinical signs (lower IVCM scores) for the animals treated with the unpreserved ATs. Benzalkonium chloride treatment decreased goblet cell count by 37.5%. While the soft-preserved Systane Balance(®) and Optive(®) and the preservative-free Vismed(®) had no effect on the goblet cell count, Cationorm increased this count by almost 40%. Interestingly, inflammatory cell infiltration in the stroma was at its lowest following treatment with the preservative-free Cationorm. Cationorm is also the only AT decreasing IL6- and IL8-stimulated secretion by 59% and 74%, respectively.

Conclusion: By restoring an adequately hydrated ocular surface environment, the different ATs promote corneal epithelium healing. These data position Cationorm as a promising AT for the management of signs and symptoms of dry eye in patients with mild to moderate dry eye disease presenting chronic subclinical levels of ocular inflammation.

Citing Articles

Cationic nanoemulsion vs. 0.15% sodium hyaluronate artificial tears in the healing process following modern surface keratorefractive surgery.

Jaworski D, Cieslinska-Rypolc A, Jadczyk-Sorek K, Jaworowska-Cieslinska I, Bubala-Stachowicz B, Mrukwa-Kominek E Eur J Ophthalmol. 2023; 33(6):2178-2184.

PMID: 37070148 PMC: 10590016. DOI: 10.1177/11206721231169540.


Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review.

Daull P, Garrigue J, Liang H, Baudouin C J Ocul Pharmacol Ther. 2023; 39(4):240-251.

PMID: 37015075 PMC: 10178935. DOI: 10.1089/jop.2022.0155.


Thermogels containing sulfated hyaluronan as novel topical therapeutics for treatment of ocular surface inflammation.

Nguyen D, Luo L, Lai J Mater Today Bio. 2021; 13:100183.

PMID: 34927046 PMC: 8649391. DOI: 10.1016/j.mtbio.2021.100183.


Nanoemulsions as Ophthalmic Drug Delivery Systems.

Dhahir R, Al-Nima A, Al-Bazzaz F Turk J Pharm Sci. 2021; 18(5):652-664.

PMID: 34708428 PMC: 8562122. DOI: 10.4274/tjps.galenos.2020.59319.


Dry eye: why artificial tears are not always the answer.

Kim M, Lee Y, Mehra D, Sabater A, Galor A BMJ Open Ophthalmol. 2021; 6(1):e000697.

PMID: 33907713 PMC: 8039249. DOI: 10.1136/bmjophth-2020-000697.


References
1.
Pal-Ghosh S, Pajoohesh-Ganji A, Menko A, Oh H, Tadvalkar G, Saban D . Cytokine deposition alters leukocyte morphology and initial recruitment of monocytes and γδT cells after corneal injury. Invest Ophthalmol Vis Sci. 2014; 55(4):2757-65. PMC: 4004424. DOI: 10.1167/iovs.13-13557. View

2.
Calonge M, Enriquez-de-Salamanca A, Diebold Y, Gonzalez-Garcia M, Reinoso R, Herreras J . Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm. 2010; 18(4):244-53. DOI: 10.3109/09273941003721926. View

3.
Aragona P, Papa V, Micali A, Santocono M, Milazzo G . Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002; 86(2):181-4. PMC: 1771021. DOI: 10.1136/bjo.86.2.181. View

4.
Daull P, Lallemand F, Garrigue J . Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol. 2013; 66(4):531-41. PMC: 4283994. DOI: 10.1111/jphp.12075. View

5.
Gumus K, Cavanagh D . The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca. Clin Ophthalmol. 2009; 3:57-67. PMC: 2709015. View